Gut Microbiota's Role in CKD-Mineral and Bone Disorder: Mechanisms and Treatments

Overview

Gut microbiota dysbiosis is a key factor in the development and progression of chronic kidney disease-mineral and bone disorder (CKD-MBD) through the gut-kidney-bone axis. Altered microbial metabolites and immune dysregulation exacerbate renal injury and bone metabolism abnormalities, while microbiota-targeted interventions show promise in improving outcomes.

Background

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is characterized by disturbances in mineral metabolism and bone homeostasis. The gut microbiota, a complex community of over 100 trillion microbial cells, plays a critical role in nutrient metabolism, immune regulation, and maintaining intestinal barrier integrity. Dysbiosis of the gut microbiota contributes to chronic low-grade inflammation and metabolic disturbances that link CKD with skeletal diseases such as rheumatoid arthritis, osteoarthritis, and osteoporosis. The gut-kidney-bone axis represents an interconnected network through which gut microbiota influences both renal and bone health.

Data Highlights

The gut microbiota produces short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which support intestinal barrier function and modulate immune responses. Dysbiosis leads to reduced SCFAs and accumulation of uremic toxins such as indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide (TMAO), exacerbating CKD and bone disorders. Key bacterial genera involved include Prevotella, Ruminococcus, Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii, and Akkermansia muciniphila, which contribute to vitamin synthesis and anti-inflammatory metabolite production.

Key Findings

• Gut microbiota dysbiosis impairs the intestinal barrier, promoting endotoxin translocation and chronic low-grade inflammation in CKD-MBD.
• Altered microbial metabolites, including decreased SCFAs and increased uremic toxins, exacerbate renal injury and disrupt bone metabolism.
• The gut-kidney-bone axis facilitates bidirectional communication among these organs via microbial metabolites and endocrine pathways such as the FGF23-Klotho axis and parathyroid hormone regulation.
• Shared and disease-specific gut microbiota dysbiosis patterns exist across CKD, rheumatoid arthritis, osteoarthritis, and osteoporosis, contributing to chronic inflammation and metabolic dysfunction.
• Interventions targeting the gut microbiota, including probiotics, prebiotics, synbiotics, dietary fiber, and fecal microbiota transplantation, show potential to modulate this axis and improve bone and kidney health.

Clinical Implications

Understanding the role of gut microbiota in CKD-MBD highlights the potential for microbiome-targeted therapies to mitigate disease progression and improve bone health. Clinicians should consider strategies that restore microbial balance and enhance beneficial metabolite production as adjunctive treatments in managing CKD and associated bone disorders.

Conclusion

Gut microbiota dysbiosis is a central mechanism linking chronic kidney disease and mineral and bone disorders via the gut-kidney-bone axis. Targeting this axis offers promising avenues for novel therapeutic interventions in CKD-MBD and related osteoarticular diseases.

Related Resources & Content

1. Author/Source/Year -- The Role of Gut Microbiota in Chronic Kidney Disease-Mineral and Bone Disorder